On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has ...
Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting ...
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
Medpage Today on MSN9d
Radiographic PFS in Metastatic CRPC More Than Doubles With Novel CombinationRadiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
The Muscular Dystrophy Association celebrates this new more accessible treatment option for people living with SMA. MDA - New ...
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...
Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback